Effectiveness of Injectable Extended-Release Naltrexone vs Daily Buprenorphine-Naloxone for Opioid Dependence | Zendy

Lars Tanum | Zendy; Kristin Klemmetsby Solli | Zendy; Zill-E-Huma Latif | Zendy; Jūratė Šaltytė Benth | Zendy; Arild Opheim | Zendy; Kamni SharmaHaase | Zendy; Peter Krajči | Zendy; Nikolaj Kunøe | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Effectiveness of Injectable Extended-Release Naltrexone vs Daily Buprenorphine-Naloxone for Opioid Dependence

Author(s) -

Lars Tanum,

Kristin Klemmetsby Solli,

Zill-E-Huma Latif,

Jūratė Šaltytė Benth,

Arild Opheim,

Kamni SharmaHaase,

Peter Krajči,

Nikolaj Kunøe

Publication year - 2017

Publication title -

jama psychiatry

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.531

H-Index - 365

eISSN - 2168-6238

pISSN - 2168-622X

DOI - 10.1001/jamapsychiatry.2017.3206

Subject(s) - buprenorphine , medicine , naltrexone , randomized controlled trial , opioid use disorder , heroin , opioid , abstinence , randomization , (+) naloxone , anesthesia , naloxone hydrochloride , adverse effect , pharmacology , psychiatry , drug , receptor

To date, extended-release naltrexone hydrochloride has not previously been compared directly with opioid medication treatment (OMT), currently the most commonly prescribed treatment for opioid dependence.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research